Key facts
- This page summarizes Kenneth C. Frazier's Form 4 filing for Merck & Co., Inc. (MRK).
- 5 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Nov 2022, 15:56.
Kenneth C. Frazier - 07 Nov 2022 Form 4 Insider Report for Merck & Co., Inc. (MRK)
- Reporting relationship
- Executive Chair, Director
- Issuer ticker
- MRK
- Reported as of
- 07 Nov 2022
- Net transaction value
- -$23,471,433
- SEC form
- 4
- Accepted by SEC
- 08 Nov 2022, 15:56:54 UTC
- Prior SEC filing
- 07 Nov 2022
- Next SEC filing
- 06 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kelly E. W. Grez as Attorney-in-Fact for Kenneth C. Frazier
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kenneth C. Frazier filed Form 4 for Merck & Co., Inc. (MRK) on 08 Nov 2022.
Change
- Previous filing in this sequence was filed on 07 Nov 2022.
- Current net transaction value: -$23,471,433.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRK
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +235,769
- Change %
- +34%
- Price
- $0.000000
- Shares after
- 936,422
- Date
- 07 Nov 2022
- Ownership
- Direct
MRK
transaction
Common Stock
Sale
- Transaction value
- $2,452,880
- Shares
- -24,914
- Change %
- -2.7%
- Price
- $98.45
- Shares after
- 911,508
- Date
- 07 Nov 2022
- Ownership
- Direct
- Footnotes
- F1
MRK
transaction
Common Stock
Sale
- Transaction value
- $12,540,835
- Shares
- -126,134
- Change %
- -14%
- Price
- $99.42
- Shares after
- 785,374
- Date
- 07 Nov 2022
- Ownership
- Direct
- Footnotes
- F2
MRK
transaction
Common Stock
Sale
- Transaction value
- $8,477,717
- Shares
- -84,721
- Change %
- -11%
- Price
- $100.07
- Shares after
- 700,653
- Date
- 07 Nov 2022
- Ownership
- Direct
- Footnotes
- F3, F4
MRK
holding
Common Stock - 401(k) Plan
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,481
- Date
- 07 Nov 2022
- Ownership
- By 401(k)
- Footnotes
- F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRK
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -235,769
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 07 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 235,769
- Exercise price
- $53.06
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.7400 to $98.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.7500 to $99.7500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.7600 to $100.3400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
Footnote F4
Holdings include shares acquired in dividend reinvestment transactions.
Footnote F5
Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.
Footnote F6
The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.